Meeting
2015 Gastrointestinal Cancers Symposium
Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
Authors
Matheus Bongers Alessandretti
Centro Oncológico Antônio Ermírio de Moraes, São Paulo, Brazil
Matheus Bongers Alessandretti , Raphael Brandao Moreira , Erika Pereira Brandao , Jessica Ribeiro Gomes , Marcus Paulo Fernandes Amarante , Aline Da Rocha Lino , Rodnei Merlrina Martins Junior , Carina Mina Abrahao , Tarcia Tarciane Soares de Sousa , Renata D'Alpino Peixoto , Marcelo Rocha Cruz , Fernando C. Maluf , Antonio C. Buzaid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 468)
DOI
10.1200/jco.2015.33.3_suppl.468
Abstract #
468
Poster Bd #
E35
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Quality Care Symposium
Treatment patterns, toxicity, and outcomes of elderly patients with advanced pancreatic cancer receiving first-line chemotherapy.
First Author: Robert Kudlovich
Poster
2017 Gastrointestinal Cancers Symposium
Modified FOLFIRINOX regimen in advanced biliary tract adenocarcinoma.
First Author: Amit Rauthan
Poster
2022 ASCO Annual Meeting
Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).
First Author: Philip Agop Philip
Poster
2019 ASCO Annual Meeting
Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.
First Author: Ali Belkouz